NIH Dives Into Comparative Effectiveness Clash With Grant Opportunities
This article was originally published in The Gray Sheet
Executive Summary
A 181-page grant application 1request from the National Institutes of Health has struck a nerve among congressional lawmakers debating the particulars of comparative-effectiveness research and comprehensive health reform
You may also be interested in...
Cardiac Imaging and CER: The Search for Efficiency
Regardless of the final shape of health care reform legislation, there is little doubt that the swirling debate around that issue has highlighted an unambiguous need to reduce health system costs, increase efficiency, and improve patient outcomes. This is particularly true for high-cost diagnostics in crucial areas like cardiac care. The focus on fast-rising care costs has ratcheted up the pressure to reduce the number and fine-tune the quality of cardiac imaging procedures. And perhaps nothing signifies change in this area more than the introduction of comparative effectiveness research into the equation in the search for standards of care.
Cardiac Imaging and CER: The Search for Efficiency
Regardless of the final shape of health care reform legislation, there is little doubt that the swirling debate around that issue has highlighted an unambiguous need to reduce health system costs, increase efficiency, and improve patient outcomes. This is particularly true for high-cost diagnostics in crucial areas like cardiac care. The focus on fast-rising care costs has ratcheted up the pressure to reduce the number and fine-tune the quality of cardiac imaging procedures. And perhaps nothing signifies change in this area more than the introduction of comparative effectiveness research into the equation in the search for standards of care.
Device Comparative Effectiveness Studies Received $40 Mil. From NIH In '09
The National Institutes of Health handed out about $40 million of its comparative effectiveness research funds in 2009 to studies directly impacting devices, with more than two-thirds of that money targeting medical imaging or in vitro diagnostics applications